Qijia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qijia Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- He Zhou
Shantou University Medical College
1 shared publication - Jiarui Guo
Shantou University Medical College
1 shared publication - Liyun Chen
Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, China
1 shared publication - Mengting Hu
Shantou University Medical College
1 shared publication - Shijie Tang
Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, China
1 shared publication - Wancong Zhang
Department of Plastic Surgery and Burns Center, Second Affiliated Hospital, Shantou University Medical College
1 shared publication
Latest Publications
- Open Access
Identifying Potential Drug Targets for Varicose Veins through Integration of GWAS and eQTL Summary Data
Background: Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment. Methods: This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org )data to identify and screen the remaining genes and identified four drug targets for the treatment of VV. Results: We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1 , PLEKHA5 , and CBWD1 , was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy. Conclusion: This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.
Open AccessIdentifying Potential Drug Targets for Varicose Veins through Integration of GWAS and eQTL Summary Data
Background: Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment. Methods: This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org )data to identify and screen the remaining genes and identified four drug targets for the treatment of VV. Results: We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1 , PLEKHA5 , and CBWD1 , was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy. Conclusion: This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.